Clinical trial NCT01282060: Association Between Glycaemic Control and Morbi/Mortality After 5 Years of Follow-up in Type 2 Diabetic Patients
Official title: Association Between Glycaemic Control and Morbi/Mortality After 5 Years of Follow-up in Type 2 Diabetic Patients
Study type: OBSERVATIONAL
Overall status: UNKNOWN
Conditions: Type 2 Diabetes
Keywords: HBA1C
DIABETES-RELATED COMPLICATIONS
GLYCAEMIC BALANCE
Lead sponsor: Association Pour la Recherche en Diabetologie et en Geriatrie
Sponsor class: OTHER
Collaborators: name: Novo Nordisk A/S
name: Umanis
First posted: 2011-01-24
Enrollment: 986
Sex: ALL
Minimum age (years): 70
Standard ages: OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: * Patients suffering from type 2 diabetes and aged 70 and over.
* Having received medicinal or non-medicinal therapy (in the case of diabetics treated with insulin, the lengh of time between diagnosis of diabtees and the introduction of insulin therapy is at least 6 months).
* Suffering from type 2 diabetes at least one year.
* With autonomy defined by a score greater than or equal to 3/6 on the ADL scale and able of being followed-up during hospital or private consultations over the next 5 years.
* Patients who did not refuse to participate in the study after receiving information on the study (Patient Information Leaflet).

The patient are monitored in the hospital or private sector throughout Metropolitan France.

Brief summary: The purpose of this study is to asses the link between glycaemic balance (summarised by HBA1C LEVEL) and specific causes of death.

Detailed description: The GERODIAB study is the first prospective, longitudinal follow-up cohort study, the main aim of which is to assess the link between glycaemic balance (evaluated on the basis of HbA1c levels) and total mortality at 5 years in diabetic patients aged 70 and over, and suffering from type 2 diabetes. An extension to 10 years is considered given the innovative features of this cohort follow-up procedure.

The secondary endpoints are as follows:

* To assess the link between glycaemic balance and the mortality rate with specific causes.
* To assess the link between glycaemic balance and the onset of or change in diabetes-related complications: cardiovascular diseases, change in renal function, diabetic retinopathy, peripheral neuropathy, perforating ulcer of the foot and acute metabolic complications.
* To assess the link between glycaemic balance and nutritional status, the onset of or changes in cognitive disorders and a loss of autonomy.
* To specify the role of other cardiovascular risk factors combined with glycaemic balance, in mortality, diabetes-related complications, cognitive disorders and loss of autonomy.

Eligibility criteria: Inclusion Criteria:

* Patient with type 2 diabetes, aged 70 and over,
* Patient having received medicinal or non-medicinal treatment (in the case of diabetics treated with insulin, the length of time between diagnosis of diabetes and the onset of insulin therapy will be at least 2 years),
* Diabetes diagnosed for at least one year,
* Patient with autonomy defined by a score greater than or equal to 3/6 on the ADL scale,
* Patient who can be monitored during hospital or private consultations over the next 10 years,
* Patient who did not refuse to take part in the study after receiving information on the study (Patient Information Leaflet), Patients are monitored in the hospital or private sector throughout France.

Exclusion Criteria:

* Patient with type 1 diabetes,
* Patient with secondary diabetes (mainly corticosteroid-induced),
* Patient with a loss of autonomy defined by a score of less than 3/6 on the ADL scale,
* Patient who cannot be monitored in the months or years to come,
* Patient in an acute situation (transient exclusion criterion),
* Patient expressing their refusal to participate in the study.

Primary outcomes:
measure: Link between HbA1c level and the overall mortality rate at 5 years.
timeFrame: 5 years
Secondary outcomes:
measure: Link between HbA1c level and specific causes of death.
timeFrame: 5 years
measure: Link between HbA1c level and the onset of or changes in diabetes-related complications
timeFrame: 5 years
measure: Link between HbA1c level and nutritional status.
timeFrame: 5 years
measure: Link between HbA1c level and the onset of or changes in cognitive disorders.
timeFrame: 5 years
measure: Link between HbA1c level and loss of autonomy.
timeFrame: 5 years
measure: Role of other cardiovascular risk factors
timeFrame: 5 years
Other outcomes:
Locations:
Study officials:
References:
citation: Doucet J, Verny C, Bordier L, Rekik A, Zulfiqar AA, Bezerra CB, Bauduceau B. Evolution in geriatric syndromes and association with survival over 5 years in the GERODIAB cohort of older French diabetic patients. Eur Geriatr Med. 2021 Jun;12(3):619-625. doi: 10.1007/s41999-020-00425-9. Epub 2020 Nov 22.
citation: Doucet J, Verny C, Balkau B, Scheen AJ, Bauduceau B. Haemoglobin A1c and 5-year all-cause mortality in French type 2 diabetic patients aged 70 years and older: The GERODIAB observational cohort. Diabetes Metab. 2018 Dec;44(6):465-472. doi: 10.1016/j.diabet.2018.05.003. Epub 2018 May 18.
citation: Bauduceau B, Le Floch JP, Halimi S, Verny C, Doucet J; SFD/SFGG Intergroup. Cardiovascular Complications Over 5 Years and Their Association With Survival in the GERODIAB Cohort of Elderly French Patients With Type 2 Diabetes. Diabetes Care. 2018 Jan;41(1):156-162. doi: 10.2337/dc17-1437. Epub 2017 Nov 7.